Heyu Biological Technology Co., Ltd. (OTCMKTS:HYBT) is a Nanjing-based biotechnology company specializing in the research, development, manufacturing and distribution of in vitro diagnostic (IVD) reagents, instruments and related consumables. Established in 2008, the company has built a vertically integrated platform that spans from early-stage assay design and clinical validation to large-scale production under ISO 13485 certification. Its core mission centers on delivering high-quality diagnostic solutions to hospitals, clinical laboratories and point-of-care settings.
The company’s product portfolio includes immunoassay kits for tumor markers, infectious diseases and cardiovascular indicators, molecular diagnostics reagents for pathogen detection, as well as automated analyzers and supporting consumables. Heyu has invested in proprietary monoclonal antibody technology and nucleic acid amplification methods, positioning itself to address emerging public health challenges. Its reagent lines carry CE marking and have secured approvals from China’s National Medical Products Administration (NMPA), reflecting compliance with stringent quality and safety standards.
Domestically, Heyu has established a distribution network covering more than 30 provinces, autonomous regions and municipalities across China. The company also maintains strategic partnerships in Southeast Asia and parts of Eastern Europe, where it supplies diagnostic kits and instruments to government health agencies and private laboratory chains. Ongoing efforts to expand its global footprint include collaboration agreements with regional distributors and participation in international trade exhibitions.
Leadership is anchored by CEO Dr. Jianhua Chen, whose background in clinical biochemistry and diagnostic R&D has steered Heyu’s product innovation strategy. The management team includes seasoned experts in regulatory affairs, quality control and commercial operations. With a growing R&D team and manufacturing capacity exceeding 5 million test units per year, Heyu Biological Technology aims to broaden its diagnostic pipeline and support precision medicine initiatives worldwide.
AI Generated. May Contain Errors.
